WuXi Biologics (WXXWY) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

WXXWY · Stock Price

USD 8.40+2.41 (+40.23%)

Market Cap: $17.9B

Historical price data

Market Cap: $17.9BPipeline: 1 drug (1 Phase 3)Founded: 2014Employees: 12,000+HQ: Wuxi, China

Sector Ranking#63 in Biologics / Biosimilars #11 in Cell & Gene Therapy

Overview

WuXi Biologics has rapidly ascended to become a top-tier global biologics CDMO, driven by its integrated 'CRDMO+' service model and massive manufacturing capacity expansion. Its mission is to enable partners to develop and manufacture biologics from concept to commercialization efficiently. The company's strategy centers on being a single-source provider, leveraging proprietary technologies like WuXiBody™ and a vast global network of facilities to serve a diverse and growing client portfolio.

Biotech

Technology Platform

Integrated 'CRDMO+' platform offering end-to-end biologics services from discovery to commercial manufacturing, powered by proprietary technologies like the WuXiBody™ bispecific antibody discovery platform.

Pipeline

1

1 drug in pipeline1 in Phase 3

Drug	Indication	Stage	Watch
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI...	NSCLC	Phase 3

Funding History

3

Total raised:$936M

PIPE$403MHillhouse CapitalFeb 15, 2021

IPO$503MMorgan StanleyJun 13, 2017

Series A$30MHillhouse CapitalJun 15, 2015

Opportunities

The global biologics CDMO market is growing rapidly, driven by increased outsourcing, the rise of virtual biotechs, and demand for complex next-generation therapies.

WuXi's global dual-sourcing strategy and massive capacity position it to capture significant market share.

Risk Factors

Geopolitical tensions, particularly between the US and China, pose a major threat to its integrated business model.

Additional risks include client concentration, execution risk in its aggressive global expansion, and potential industry overcapacity.

Competitive Landscape

Competes with global CDMO leaders like Lonza, Samsung Biologics, and Catalent. Its key advantages are its fully integrated 'CRDMO+' model, massive scale, proprietary technology (WuXiBody™), and cost-efficient operations complemented by a growing Western footprint.